Some GLP-1 companies facing lawsuits over vision loss. What to know

Live updates

1. 5d ago

   Novo Nordisk and Eli Lilly Face New Vision Loss Lawsuits

   Novo Nordisk and Eli Lilly are facing legal action over allegations that GLP-1 medications cause vision loss. Recent filings specifically link drugs like Mounjaro and Ozempic to Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION). Plaintiffs claim manufacturers ignored or downplayed these risks. These cases are part of a broader wave of litigation including thousands of claims regarding bowel injuries and neurological damage. While drug makers deny the allegations, federal courts are currently managing the vision-loss claims within multidistrict litigation.

   Why it matters

   GLP-1 drugs are widely used for diabetes and weight loss. These lawsuits center on whether companies failed to warn users about permanent blindness. The legal outcome depends on whether the vision loss is a direct result of the medication or a standard complication of diabetes.

   Still unconfirmed

   • Novo Nordisk ignored and downplayed risks of vision loss linked to Ozempic.
   • Mounjaro is linked to cases of NAION vision loss.

   What to watch next

   • Court rulings on early motion practice in MDL 3163.
   • Regulatory agency updates on GLP-1 safety risks.
   Sources used for this update (4)

   1. unblock.federalregister.gov — Federal Register :: Removal of Automatic Extensions for Certain Employment Authorization Documents
   2. www.aboutlawsuits.com — Ozempic Blindness Lawsuit Alleges Novo Nordisk Concealed ...
   3. toptier.legal — GLP-1 NAION News | U.S. Ozempic Vision MDL 3163 | Top Tier Legal
   4. finscans.com — Eli Lilly Faces Multiple Lawsuits Over Mounjaro Vision Loss ...
   confidence 70%
2. 8d ago

   GLP-1 Makers Face Mounting Lawsuits Over Vision Loss and Injuries

   Manufacturers of popular GLP-1 medications face thousands of lawsuits accusing them of failing to warn patients about severe health risks, including permanent blindness, bowel injuries, and neurological damage. Federal court filings show hundreds of vision-loss cases and thousands of stomach-injury cases pending in multidistrict litigation against companies like Novo Nordisk and Eli Lilly. While drug makers deny these claims, regulatory agencies continue to evaluate the safety risks of medications such as Ozempic, Wegovy, Mounjaro, Zepbound, and Rybelsus.

   Why it matters

   The rising tide of litigation coincides with broader insurance and financial shifts surrounding weight-loss treatments, as numerous employer-sponsored healthcare plans drop coverage due to soaring costs. This legal battle centers on whether pharmaceutical companies adequately informed consumers and medical professionals about potentially irreversible side effects before widespread adoption of these drugs surged.

   What is confirmed

   • Thousands of lawsuits accuse makers of GLP-1 weight-loss drugs of failing to warn patients about risks including blindness, bowel injuries, and neurological damage.
   • Pending actions in federal court include 247 vision-loss cases and 4,025 stomach-injury cases as of October 1, 2026.
   • The multidistrict litigation involves claims against manufacturers Novo Nordisk and Eli Lilly over medications such as Ozempic, Wegovy, Mounjaro, Zepbound, and Rybelsus.

   Still unconfirmed

   • Some individual plaintiffs allege that they suffered irreversible blindness and severe gastrointestinal side effects directly caused by GLP-1 medications.

   What to watch next

   • Upcoming expert rulings and court decisions within MDL 3094
   • Further updates from the FDA regarding GLP-1 side effect evaluations
   Sources used for this update (14)

   1. www.centraloregondaily.com — 'My colon blew up': lawsuits mount over GLP-1 weight-loss drugs
   2. retiredamericans.org — Friday Alert Archives - Retired Americans
   3. www.motleyrice.com — Weight Loss Drug Lawsuits | Learn More About GLP-1 Lawsuits
   4. www.motleyrice.com — Zepbound® Lawsuit: Who Qualifies and Latest Health Risks
   5. www.motleyrice.com — Rybelsus® Lawsuit | GLP-1 RA Medication 2026 Legal Updates
   6. www.cnbc.com — GLP-1 drug coverage is being dropped by employer plans: What to know about 2027 weight-loss options
   7. lawfold.com — GLP Lawsuit (Updated October 2026) - lawfold.com
   8. www.newsbreak.com — Cathie Wood Predicts Oil Crashing to $30-$35 a Barrel as EVs Take Over Transportation: Says Demand Is 'Peaking’
   9. medshadow.org — GLP-1 Lawsuits Raise Questions About Vision Loss and Other Serious Side Effects
   10. lawfold.com — Ozempic Lawsuit 2 Billion (Updated October 2026)
   11. lawfold.com — Rybelsus Lawsuit (Updated November 2026) - lawfold.com
   12. www.motleyrice.com — Wegovy® Lawsuit | October 2026 Legal Updates - Motley Rice
   confidence 90%
3. 16d ago

   GLP-1 lawsuits over vision loss mount, 4,025 cases pending

   Hundreds of lawsuits allege GLP-1 medications like Ozempic, Wegovy, and Mounjaro cause vision loss. As of October 1, 2026, 247 vision-loss cases and 4,025 stomach-injury cases are pending in federal court. Manufacturers deny claims, while the FDA evaluates risks. Lawsuits claim failure to warn users about potential vision loss, with some plaintiffs alleging irreversible blindness.

   Why it matters

   The lawsuits involve GLP-1 medications used for weight loss and diabetes treatment. Plaintiffs claim these medications cause Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION), leading to irreversible blindness. The cases are proceeding in multidistrict litigations in Pennsylvania.

   What is confirmed

   • Ozempic and GLP-1 lawsuits have 4,025 stomach-injury and 247 vision-loss cases pending in federal court as of October 1, 2026.
   • Lawsuits alleging vision loss are proceeding in two separate multidistrict litigations (MDLs) in Pennsylvania.
   • Manufacturers deny claims that GLP-1 medications cause vision loss.

   Still unconfirmed

   • A Maryland man claims Ozempic left him legally blind due to a failure to warn users about potential vision loss.

   What to watch next

   • FDA evaluation of risks and potential regulatory action
   • Outcome of multidistrict litigations in Pennsylvania
   • Any potential settlements or changes in GLP-1 medication warnings
   Sources used for this update (4)

   1. www.robertkinglawfirm.com — Wegovy Pill Lawsuit [2026 Update] – Severe Risks & Legal Claims
   2. www.glp1picks.com — Ozempic & GLP-1 Lawsuit Tracker 2026: 4,025 Cases Pending
   3. acdavislaw.com — Ozempic and Wegovy: What's next for stomach paralysis and ...
   4. healthfactsjournal.com — Ozempic Lawsuit Update: Claims, Status & Who Can File
   confidence 90%
4. 19d ago

   Novo Nordisk and Eli Lilly face lawsuits over GLP-1 linked vision loss

   Novo Nordisk and Eli Lilly are facing hundreds of lawsuits alleging that GLP-1 medications, including Ozempic, Wegovy, and Mounjaro, cause Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION). This condition restricts blood flow to the optic nerve and can cause irreversible blindness. While manufacturers deny the claims, the FDA is evaluating the risks to determine if regulatory action is needed. Current legal actions include a lawsuit from a Maryland man who claims the medications left him legally blind due to a failure to warn users about potential vision loss.

   Why it matters

   GLP-1 medications are widely used for weight loss and diabetes management. The lawsuits center on NAION, often described as an eye stroke. Plaintiffs seek damages for permanent blind spots and total blindness.

   What is confirmed

   • Novo Nordisk and Eli Lilly face hundreds of lawsuits alleging GLP-1 drugs cause Non-Arteritic Anterior Ischemic Optic Neuropathy.
   • NAION restricts blood supply to the optic nerve and can lead to irreversible blindness.
   • The FDA is assessing risks to decide if regulatory action is necessary.

   Still unconfirmed

   • GLP-1 injury lawsuits are proceeding without reliable frequency data.

   What to watch next

   • FDA decision on regulatory action regarding GLP-1 vision risks
   • Court rulings on the failure-to-warn claims in the Todd Engel case
   • Publication of peer-reviewed frequency data on NAION occurrences in GLP-1 users
   Sources used for this update (7)

   1. www.yahoo.com — Yahoo
   2. jen.jiji.com — Iran-US, signs of tension: Washington recalls personnel from embassies in Saudi Arabia, UAE, and Qatar
   3. jen.jiji.com — Barella: "I don't know if the victory is 100% deserved but we gave everything we had"
   4. www.robertkinglawfirm.com — Ozempic Blindness Lawsuit [2026 Update] - King Law
   5. nypost.com — Maryland man claims he went blind after taking Ozempic ...
   6. veloxpeps.com — GLP-1 Vision-Loss Claims: NAION Evidence | Velox
   7. glp1newshour.substack.com — Starving Brains, Vision Loss Lawsuits and Lilly at Vogue
   confidence 90%
5. 22d ago

   GLP-1 Manufacturers Face Lawsuits Over Permanent Vision Loss

   Novo Nordisk and Eli Lilly are facing hundreds of lawsuits alleging that GLP-1 medications like Ozempic, Wegovy, and Mounjaro cause Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION). This condition, described as an eye stroke, cuts off blood supply to the optic nerve and can lead to irreversible blindness. While manufacturers deny these claims, the FDA is currently assessing the risks to decide if regulatory action is necessary. Plaintiffs are seeking damages for permanent blindness and blind spots resulting from the injections.

   Why it matters

   GLP-1 drugs are widely used for weight loss and diabetes management. NAION is a rare condition that typically causes sudden vision loss. The legal challenges center on whether these drugs increase the risk of this specific ocular injury.

   What is confirmed

   • Novo Nordisk and Eli Lilly face hundreds of lawsuits claiming GLP-1 drugs cause NAION.
   • NAION is a condition that cuts off blood supply to the optic nerve.
   • The FDA is assessing potential risks to determine if regulatory action is warranted.

   Still unconfirmed

   • Todd Engel claims Ozempic caused total vision loss in both eyes.
   • Wegovy is linked to blurry vision and NAION.

   What to watch next

   • FDA determination on whether to mandate warning labels for GLP-1 drugs
   • Court rulings on the admissibility of NAION as a side effect of GLP-1 medications
   Sources used for this update (5)

   1. www.dailymail.com — Ozempic maker hit with lawsuits over 'eye stroke' condition
   2. www.foxnews.com — Ozempic lawsuit claims drug caused total vision loss in both ...
   3. jen.jiji.com — Guerrilla in Milan, assault on shops and looting: 200 young people stopped. Meloni convenes meeting on public order
   4. jen.jiji.com — Trump: "Zelensky doesn't want the war to end". Ukrainian president: "White House pushing Kyiv to surrender"
   5. www.robertkinglawfirm.com — Wegovy Vision Loss Lawsuit [2026 Update] - King Law
   confidence 90%
6. 25d ago

   Lawsuits allege GLP-1 drugs cause vision loss

   Hundreds of lawsuits against Novo Nordisk and Eli Lilly claim their GLP-1 medications, such as Ozempic and Mounjaro, cause NAION, a rare condition leading to sudden vision loss and irreversible blindness. The manufacturers deny these claims. The FDA is assessing potential risks to determine if regulatory action is warranted.

   Why it matters

   These lawsuits are significant as they involve popular medications used for diabetes and weight loss. The alleged side effect, NAION, can cause irreversible blindness. The outcome of these lawsuits and the FDA's assessment could impact the use and regulation of GLP-1 medications.

   What is confirmed

   • The FDA is assessing potential risks to determine if regulatory action is warranted.
   • Hundreds of lawsuits are proceeding in federal court against pharmaceutical manufacturers Novo Nordisk and Eli Lilly.

   Still unconfirmed

   • GLP-1 medications may help people live longer by slowing the body's aging processes.

   What to watch next

   • The FDA's determination on regulatory action
   • The outcome of the lawsuits against Novo Nordisk and Eli Lilly
   • Further research on the link between GLP-1 medications and NAION
   Sources used for this update (2)

   1. www.foxnews.com — Fox News - Breaking News Updates | Latest News Headlines | Photos...
   2. www.wbaltv.com — Could GLP-1 drugs be anti-aging medications? - WBAL
   confidence 80%
7. 28d ago

   GLP-1 Makers Face Lawsuits Over Vision Loss and NAION

   Hundreds of lawsuits are proceeding in federal court against pharmaceutical manufacturers Novo Nordisk and Eli Lilly over popular GLP-1 medications like Ozempic, Wegovy, and Mounjaro. Plaintiffs allege these drugs trigger a rare, sight-robbing condition known as NAION, which causes sudden vision loss and irreversible blindness. Manufacturers deny the claims, while experts and legal teams debate the extent of the evidence linking the medications to the eye injury. The Food and Drug Administration is currently assessing potential risks to determine if regulatory action is warranted.

   Why it matters

   Blockbuster diabetes and weight-loss drugs have achieved massive commercial success while facing increasing scrutiny over side effects. Scant data regarding serious adverse events complicates scientific and legal efforts to determine how frequently these severe health issues occur. Legal proceedings continue as patients demand adequate warnings for irreversible visual impairment.

   What is confirmed

   • Pharmaceutical companies Novo Nordisk and Eli Lilly face lawsuits over GLP-1 medications like Ozempic, Wegovy, and Mounjaro.
   • Lawsuits allege that GLP-1 drugs cause NAION, a rare condition resulting in sudden vision loss and blindness.
   • Lawyers are pursuing claims over gastroparesis and vision loss side effects.
   • The FDA is assessing possible NAION risks to decide whether regulatory action is needed.

   Still unconfirmed

   • Over 1,000 reports of eye damage linked to GLP-1 drugs have been filed with the FDA since 2024.

   What to watch next

   • Decisions by the FDA on whether regulatory action is needed following its assessment of NAION risks.
   • Developments in the federal multidistrict litigation consolidating claims against GLP-1 manufacturers.
   Sources used for this update (14)

   1. www.consumernotice.org — Ozempic Blindness Lawsuit 2026: NAION Claims & Who Qualifies
   2. www.thetechedvocate.org — Vision Loss Nightmare: Popular Weight Loss Drugs Spark 200+ Lawsuits
   3. www.aboutlawsuits.com — Ozempic Lawsuit, Wegovy Lawsuit and Mounjaro Lawsuit ...
   4. jen.jiji.com — Superenalotto, 5+1 wins 518 thousand euros: today's winning combination 8 October
   5. www.ibtimes.co.uk — Starbucks Is Being Sued Over 'Sugar-Free' Protein Lattes That ...
   6. www.devdiscourse.com — Reuters Health News Summary
   7. www.drugwatch.com — I Interviewed One of the Lead Attorneys in the Ozempic Vision ...
   8. www.medscape.com — GLP-1s and NAION: Do Patients Need a Warning? - Medscape
   9. lawsuitinformer.com — Ozempic Vision Loss Lawsuits: NAION Explained
   10. www.wlrn.org — Ongoing lawsuits allege GLP-1s can cause serious harm. But we don't know how often | WLRN
   11. www.healthmarkets.com — Healthcare Reform News Updates | Healthmarkets
   12. theclinicaltimes.com — Patients sue GLP-1 makers over alleged vision loss and other ...
   confidence 90%
8. 34d ago

   GLP-1 companies face lawsuits over vision loss claims

   Hundreds of lawsuits allege GLP-1 medications like Ozempic, Wegovy, and Mounjaro cause NAION, a rare condition resulting in sudden vision loss. Plaintiffs claim manufacturers failed to provide adequate warnings about these risks. The manufacturers deny these claims. A federal MDL is consolidating claims. Plaintiffs seek damages for irreversible blindness and visual impairment.

   Why it matters

   The surge in GLP-1 medication use, now at 11% of U.S. adults, has led to increased scrutiny of potential side effects. Lawsuits against Novo Nordisk and Eli Lilly, the manufacturers of these medications, have been mounting. The cases involve allegations of failure to warn patients about the risk of NAION.

   What is confirmed

   • GLP-1 drugs like Ozempic and Wegovy are linked to NAION sudden vision loss.
   • A federal MDL (No. 3163) is consolidating claims related to GLP-1 drugs and NAION vision loss.
   • Plaintiffs argue manufacturers failed to provide adequate warnings about the risks of NAION.

   What to watch next

   • The outcome of the federal MDL (No. 3163)
   • Any rulings on the Ozempic and GLP-1 cases after the September expert hearing
   • Settlements and payouts in the ongoing lawsuits
   Sources used for this update (5)

   1. peoplesjustice.info — GLP-1 Vision Loss (Ozempic / Wegovy NAION) Lawsuit
   2. www.robertkinglawfirm.com — Trulicity Eye Side Effects Lawsuit [2026 Update] - King Law
   3. lawsuittracker.org — Ozempic Lawsuit – October 2026 Update | Lawsuit Tracker
   4. lawsuitinformer.com — Ozempic Lawsuit Update October 2026: Waiting on a Ruling
   5. www.drugwatch.com — Mounjaro (Tirzepatide): Side Effects, Risks & FDA Warnings
   confidence 90%
9. 36d ago

   GLP-1 Use Rises Amid Vision Loss Lawsuits

   U.S. adult use of GLP-1 medications like Ozempic, Wegovy, and Mounjaro has increased to 11%, according to Gallup data. This surge occurs as Novo Nordisk and Eli Lilly face hundreds of lawsuits alleging their drugs cause NAION, a rare condition resulting in sudden vision loss. Plaintiffs argue the companies failed to provide adequate warnings about these risks. The manufacturers deny these claims while patients seek damages for irreversible blindness and visual impairment.

   Why it matters

   NAION is a rare eye condition that can cause permanent sight loss. These medications are widely used for weight loss and diabetes management. The litigation focuses on whether pharmaceutical companies suppressed known risks.

   What is confirmed

   • Gallup data indicates 11% of U.S. adults use GLP-1 medications such as Ozempic, Wegovy, and Mounjaro.
   • U.S. adult use of these drugs was 3% in 2024.

   Still unconfirmed

   • GLP-1 medications increase the risk of NAION and sudden vision loss.
   • Novo Nordisk and Eli Lilly failed to adequately warn users of potential vision risks.

   What to watch next

   • Court rulings on the admissibility of NAION risk evidence
   • Updated clinical data on the correlation between GLP-1s and vision loss
   Sources used for this update (2)

   1. www.fox5vegas.com — Weight-loss drug use surges as lawsuits and side-effect concerns grow - FOX5 Vegas
   2. timesofindia.indiatimes.com — 8 Most expensive fruits in the world that are worth possessing
   confidence 90%
10. 38d ago

    Hundreds sue GLP-1 drugmakers over vision loss claims

    Hundreds of lawsuits are filed against manufacturers of GLP-1 medications, such as Ozempic, Wegovy, and Mounjaro, alleging the drugs increase the risk of a rare eye condition called NAION, leading to sudden vision loss. Plaintiffs claim they were not adequately warned of this potential risk. Defendants, including Novo Nordisk and Eli Lilly, dispute these claims. The lawsuits seek accountability for irreversible blindness and visual impairment.

    Why it matters

    The legal actions center on claims that drugmakers failed to provide adequate warnings regarding NAION, a rare form of optic nerve damage. This condition can cause sudden and irreversible vision loss. As patients seek accountability, researchers continue to examine the possible association between GLP-1 treatments and NAION. The mounting lawsuits reflect growing concerns over the safety of these popular weight-loss and diabetes medications.

    What is confirmed

    • Patients allege that GLP-1 medications like Ozempic, Wegovy, and Mounjaro caused NAION, a rare form of optic nerve damage.
    • Hundreds of lawsuits have been filed against GLP-1 drugmakers over vision loss claims.
    • Defendants, including Novo Nordisk and Eli Lilly, dispute the claims of vision loss associated with GLP-1 medications.

    Still unconfirmed

    • A Georgia nurse practitioner claims she woke up with much of the vision in her right eye gone after taking a weight-loss drug.

    What to watch next

    • The outcome of ongoing lawsuits against GLP-1 drugmakers
    • Further research on the association between GLP-1 treatments and NAION
    • FDA warnings or actions regarding GLP-1 medications and vision loss risk
    Sources used for this update (13)

    1. www.yahoo.com — Ozempic Vision Loss Lawsuits Allege Permanent Eye Damage - Yahoo
    2. www.boston.com — Mass. man alleges in lawsuit that GLP-1 caused permanent ...
    3. www.yahoo.com — Hundreds Sue GLP-1 Drugmakers Over Vision Loss as ... - Yahoo
    4. gardnermagazine.com — Local News Gardner MA – Gardner News Magazine: Local News & Articles in Gardner MA
    5. flipboard.com — Ozempic & Mounjaro Lawsuits: Elon Musk To Oprah Winfrey And Indian Comic Who Used Weight Loss Drug
    6. www.premiumtimesng.com — US patients sue Ozempic, Mounjaro makers over vision loss - Premium Times
    7. nypost.com — Dad says he went permanently blind — in lawsuit against ...
    8. www.medicaldaily.com — Some Wet Macular Degeneration Patients May Someday Need Eye Injections Only Twice a Year After Kodiak Tri....
    9. www.lanierlawfirm.com — NAION Ozempic GLP-1 Drugs Lawsuit: September 2026 Update
    10. www.drugwatch.com — Ozempic Lawsuit: September 2026 Blindness and Gastroparesis ...
    11. timesofindia.indiatimes.com — 59-year-old dad claims Ozempic left him ‘permanently blind’ within days: What we know about vision loss due to GLP-1 and the lawsuits
    12. www.drugwatch.com — Mounjaro Side Effects: Common, Serious & FDA Warnings
    confidence 85%
11. 42d ago

    GLP-1 Drugmakers Face Hundreds of Lawsuits Over Vision Loss

    Manufacturers of popular GLP-1 medications face hundreds of lawsuits alleging that drugs such as Ozempic, Wegovy, and Zepbound increase the risk of a rare eye condition causing sudden vision loss. The legal actions center on claims that drugmakers failed to provide adequate warnings regarding the condition, known as NAION. Meanwhile, manufacturers Novo Nordisk and Eli Lilly dispute the claims as lawsuits mount across the United States. Researchers continue to examine the possible association between the treatments and the rare eye stroke as patients seek accountability for irreversible blindness and visual impairment.

    Why it matters

    The legal scrutiny targets a class of highly prescribed diabetes and weight-loss medications that have surged in popularity. Patients and legal counsel argue that manufacturers should have clearly warned consumers about the potential for severe ocular side effects. Litigation tracking shows ongoing docket updates as new filings enter the legal system.

    What is confirmed

    • Hundreds of consumers are suing the manufacturers of GLP-1 receptor agonists, alleging the medications may increase the risk of a rare form of vision loss.
    • The claims focus on a rare eye condition called NAION and allegations that drugmakers failed to provide adequate warnings.
    • Popular GLP-1 medicines facing lawsuits include Ozempic, Wegovy, Zepbound, and Mounjaro.
    • Novo Nordisk and Eli Lilly have disputed the claims.

    Still unconfirmed

    • Lawsuits allege that GLP-1 medications directly caused sudden vision loss and irreversible blindness in patients.

    What to watch next

    • Further findings from ongoing researcher examinations into the association between GLP-1 drugs and NAION
    • Upcoming court filings and verdict or settlement updates on the litigation docket
    Sources used for this update (6)

    1. www.wcvb.com — Some GLP-1 companies facing lawsuits over rare condition causing vision loss
    2. nypost.com — GLP-1 drugs increase rare ‘eye stroke’ linked to vision loss, hundreds of lawsuits allege
    3. economictimes.indiatimes.com — GLP-1 vision loss lawsuit: GLP-1 users are suing over vision ...
    4. www.medicaldaily.com — Hundreds of Lawsuits Allege Ozempic and Other GLP-1 Drugs Caused Sudden Vision Loss, but Absolute Risk Ap....
    5. www.freepressjournal.in — Ozempic Causes Blindness? Patients Sue GLP-1 Drugmakers Over Rare Eye Condition Risk - Free Press Journal
    6. peoplesjustice.info — GLP-1 Vision Loss (Ozempic / Wegovy NAION) Lawsuit Tracker
    confidence 100%
12. 45d ago

    Hundreds sue GLP-1 drug makers over vision loss claims

    Hundreds of patients have filed lawsuits alleging that GLP-1 medications, including Ozempic, Wegovy, and Mounjaro, caused vision loss. The litigation centers on a rare condition described as an eye stroke. While some users report irreversible blindness, the legal actions seek to hold drug companies accountable for these side effects. The cases highlight a potential risk of a rare type of vision loss associated with these popular weight-loss and diabetes treatments.

    Why it matters

    GLP-1 receptor agonists are widely used for weight management and glycemic control. These lawsuits suggest a previously underreported risk of severe ocular damage. The outcome of these cases could impact prescribing guidelines and warning labels for these drugs.

    What is confirmed

    • Hundreds of lawsuits allege that GLP-1 medications like Ozempic, Wegovy, and Mounjaro caused vision loss.
    • The lawsuits link the medications to a rare type of vision loss described as an eye stroke.

    Still unconfirmed

    • A man from Massachusetts reports experiencing irreversible blindness as a side effect of a GLP-1 drug.
    • A woman detailed losing her vision after taking a GLP-1 medication.

    What to watch next

    • Court rulings on the admissibility of evidence linking GLP-1s to eye strokes
    • Official responses or medical data releases from manufacturers of Ozempic, Wegovy, and Mounjaro
    • FDA updates to drug warning labels regarding ocular risks
    Sources used for this update (6)

    1. ABC News - Breaking News, Latest News and Videos — What GLP-1 users should know about the potential risk of a rare type of vision loss
    2. Fox News — Popular weight-loss drugs face numerous lawsuits over rare ‘eye stroke’ linked to vision loss
    3. TODAY.com — Woman Details Losing Vision After Taking GLP-1 As Hundreds of Patients Sue Drug Companies
    4. AZ Family — Hundreds of lawsuits allege GLP-1s like Ozempic, Wegovy, Mounjaro caused vision loss
    5. WCVB — Some GLP-1 companies facing lawsuits over vision loss. What to know
    6. Boston 25 News — Irreversible blindness: Mass. man shares shocking side effect of GLP-1 drug | Full interview
    confidence 90%